Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345178 | 0.92 | DYRK1A (0.45) | SPRKDM4EALDH1A1HPGDHTT | |
| SCHEMBL6350724 | 0.89 | KDM4E (0.44) | SPRKDM4EALDH1A1HPGDHTT | |
| SCHEMBL6341115 | 0.86 | MEN1 (0.45) | SPRKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL6342646 | 0.85 | ALDH1A1 (0.48) | SPRKDM4EALDH1A1HPGDGAA | |
| SCHEMBL6341577 | 0.84 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDTHRBMAPT | |
| SCHEMBL6342408 | 0.84 | KDM4E (0.43) | SPRKDM4EALDH1A1HTTGAA | |
| SCHEMBL6343491 | 0.84 | MAPT (0.43) | KDM4EALDH1A1THRBMAPTHSD17B10 | |
| SCHEMBL6339985 | 0.84 | L3MBTL1 (0.43) | ALDH1A1HPGDTHRBMAPTHSD17B10 | |
| SCHEMBL6342518 | 0.83 | ABCG2 (0.48) | KDM4EALDH1A1HPGDHTTGAA | |
| SCHEMBL6354120 | 0.82 | CA12 (0.42) | KDM4EALDH1A1HPGDTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | SPR 1579/4885KDM4E 1741/4885ALDH1A1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.